219 related articles for article (PubMed ID: 23674566)
1. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.
Gillis JL; Selth LA; Centenera MM; Townley SL; Sun S; Plymate SR; Tilley WD; Butler LM
Oncotarget; 2013 May; 4(5):691-704. PubMed ID: 23674566
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
Shafi AA; Cox MB; Weigel NL
Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
[TBL] [Abstract][Full Text] [Related]
5. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
6. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
7. Role of androgen receptor splice variants, their clinical relevance and treatment options.
Wach S; Taubert H; Cronauer M
World J Urol; 2020 Mar; 38(3):647-656. PubMed ID: 30659302
[TBL] [Abstract][Full Text] [Related]
8. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
9. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
10. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
Saporita AJ; Ai J; Wang Z
Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
[TBL] [Abstract][Full Text] [Related]
11. Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
Ferraldeschi R; Welti J; Powers MV; Yuan W; Smyth T; Seed G; Riisnaes R; Hedayat S; Wang H; Crespo M; Nava Rodrigues D; Figueiredo I; Miranda S; Carreira S; Lyons JF; Sharp S; Plymate SR; Attard G; Wallis N; Workman P; de Bono JS
Cancer Res; 2016 May; 76(9):2731-42. PubMed ID: 27197266
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
[TBL] [Abstract][Full Text] [Related]
13. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 as a therapeutic target in prostate cancer.
Solit DB; Scher HI; Rosen N
Semin Oncol; 2003 Oct; 30(5):709-16. PubMed ID: 14571418
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
17. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.
Chan SC; Li Y; Dehm SM
J Biol Chem; 2012 Jun; 287(23):19736-49. PubMed ID: 22532567
[TBL] [Abstract][Full Text] [Related]
20. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
